| Project/Area Number |
08407043
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | KYUSHU UNIVERSITY |
|---|
Principal Investigator |
FUKUI Masashi Kyushu Univ., Neurological Institute, Dept.of Neurosurgery, Professor MD,PhD, 医学部, 教授 (10038713)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
INAMURA Takanori Kyushu Univ., Neurological Institute, Dept.of Neurosurgery, Assistant Professor, 医学部, 助手 (50274460)
IKEZAKI Kiyonobu Kyushu Univ., Neurological Institute, Dept.of Neurosurgery, Assistant Professor, 医学部, 講師 (10145360)
NISHIO Shunji Kyushu Univ., Neurological Institute, Dept.of Neurosurgery, Assistant Professor, 医学部, 講師 (10180580)
|
|---|
| Project Period (FY) |
1996 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥39,900,000 (Direct Cost: ¥39,900,000)
Fiscal Year 1998: ¥8,200,000 (Direct Cost: ¥8,200,000)
Fiscal Year 1997: ¥8,800,000 (Direct Cost: ¥8,800,000)
Fiscal Year 1996: ¥22,900,000 (Direct Cost: ¥22,900,000)
|
|---|
| Keywords | bradykinin / brain tumor / antisense oligonucleotide / microsatellite / apoptosis / chemotherapy / BBB / antisense / Treatment / Peameability / Brain tumor / Chemotherapy / Bradykinin / Antisease |
|---|
| Research Abstract |
1. Genetic characterization of malignant gliomas
We recognized the microsatellite instability in the chromosome 10 in 6 out of 31 humanﾟCgliomas. And rare apoptosis was recognized in malignant gliomas. These findingsﾟCsuggested that the genetic abnormality strongly associated with the malignantﾟCtransformation of the gliomas.
2. Establishment of quantitative measurement of antisenseoligonucleotide in theﾟCorgans.
After obtaining the organs, brain, liver, and kidney, DNA fractions was extracted using centrifugation and filters. The DNA fractions were electrophorated on the acrylamide gel and trasbiotted to the membrane. A quantitative measurement of antisenseoligonucleotide was performed using RI-labeled senseoligonucleotide.
3. Selective delivery of antisenseoligonucleotide by intracarotid bradykinin infusion We injected antisenseoligonucleotide from internal carotid artery in tumor-bearing rat. The delivered oligonucleotide was measured by the methods described above. The antisenseoligonucleotide was selectively delivered into the brain tumor by 1.4 fold, compared with the control study.
3. Effect of intracarotid bradykinin infusion on vital signs in dogs.
Using 20 dogs, we examined the effect of intracarotid bradykinin infusion on vital signs. At the dose of 1 and 2.5 gamma, intracarotid bradykinin infusion did not change the vital signs significantly. On the other hand, at the dose of 5 and 10 gamma, it changed the vital signs including cerebral blood flow at the beginning of the infusion.
|
